Abstract
There is a clear need to develop new therapies for malignant mesothelioma. Surgical management is rarely curative and few chemotherapy regimens have activity in unresectable disease. A significant percentage of mesotheliomas express CD30. Brentuximab vedotin is an anti-CD30 antibody conjugated by a protease-cleavable linker to a microtubule-disrupting agent, monomethyl auristatin E. Brentuximab vedotin (1.8 mg/kg q3wk) has induced objective response rates of 75% and 86% in patients (pts) with relapsed/refractory (r/r) Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL), respectively.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
